Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed for the first-line treatment of non-small-cell lung cancer
Summary
Pemetrexed is recommended as a possible treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) if: the cancer is a particular type (adenocarcinoma or large-cell carcinoma) and the person has not had any treatment for NSCLC before. Healthcare professionals should not ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in July 2010
About this guidance
Technology appraisals TA181
Issued: September 2009
How this guidance was produced
